Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 20, 2024
Reporting Period: Specific event date of June 20, 2024.
Context: The filing reports on a payment received under a Senior Secured Promissory Note issued by Scilex Holding Company ("Scilex") pursuant to a Securities Purchase Agreement dated September 21, 2023.
Key Financial Metrics
Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, profit, or margins as this is a current report on a specific transaction event, not a periodic financial statement.
Cash Flow: The Company received an additional payment of approximately $10.4 million on June 20, 2024.
Debt and Liquidity:
- Note Principal Amount: $101,875,000 (issued by Scilex to Oramed).
- Total Principal Received to Date: $40.0 million as of June 20, 2024.
- Recent Payment: $10.4 million applied to the third principal payment installment.
- Payment Obligation Status: The recent payment fulfilled a $20 million payment obligation.
Material Changes
The primary material change is the receipt of the $10.4 million payment from Scilex. This payment brings the cumulative total received under the Note to $40.0 million, satisfying the specific $20 million installment obligation due at that time. No other material changes to financial position or operations are detailed in this specific filing.
Guidance, Outlook, and Risks
Management Commentary: Management confirms the receipt of the payment and the fulfillment of the installment obligation. The filing includes a standard cautionary note regarding forward-looking statements.
Risks and Contingencies:
- Risk regarding the Company's ability to obtain payment of principal due pursuant to the Note.
- Potential diversion of management's attention from ongoing business operations.
- Exposure to potential litigation in connection with the transactions.
Investor Verification Checklist
- Verify the remaining principal balance on the $101,875,000 Note after the $40.0 million received.
- Confirm the schedule and terms for future principal payments under the Note.
- Review the status of the warrants to purchase Scilex common stock issued alongside the Note.
- Monitor for any updates regarding the assumption of Sorrento Therapeutics, Inc. obligations by Scilex.